Fibrates Do Not Reduce Overall Mortality
Fibrates do not reduce overall mortality or cardiovascular mortality, though they may modestly reduce composite cardiovascular events (primarily non-fatal myocardial infarction) in select patients with moderate-to-severe hypertriglyceridemia (triglycerides ≥200 mg/dL) who are not on statins. 1
Evidence on Mortality Outcomes
The Endocrine Society Clinical Practice Guideline (2012) explicitly states that "studies to date have not demonstrated an overall benefit of fibrates for reduction of cardiovascular or total mortality" 1. This represents the highest-quality guideline evidence available and should guide clinical decision-making.
Supporting research confirms this finding:
- A 2010 meta-analysis of 18 trials (45,058 participants) found no effect on all-cause mortality (RR 1.00), cardiovascular mortality (RR 1.03), or sudden death 2
- A 2014 meta-analysis of 39 trials (117,411 patients) showed no significant effect on all-cause mortality, coronary heart disease mortality, or stroke for fibrates 3
- The 2016 Cochrane review found no effect on overall mortality (RR 1.01) or non-CVD mortality (RR 1.01) 4
Where Fibrates May Have Limited Benefit
Composite Cardiovascular Events (Not Mortality)
Fibrates reduce composite cardiovascular events by approximately 10-16%, driven primarily by reduction in non-fatal MI 4, 2. However, this benefit does NOT translate to mortality reduction and the absolute risk reduction is modest (<1%) 4.
Specific Patient Populations Where Fibrates May Be Considered:
1. Moderate-to-Severe Hypertriglyceridemia (TG ≥200 mg/dL)
- Post-hoc subgroup analyses show fibrates reduce composite cardiovascular events in patients with triglycerides ≥200 mg/dL 1
- No benefit when triglycerides <200 mg/dL 1
- The American Heart Association notes greater benefit in high-risk subgroups with elevated triglycerides from Helsinki Heart Study and Bezafibrate Infarction Prevention studies 5
2. Severe/Very Severe Hypertriglyceridemia (TG ≥500-1000 mg/dL)
- Primary indication: pancreatitis prevention, NOT cardiovascular mortality reduction 1
- Fibrates should be strongly considered to maintain triglycerides <1000-2000 mg/dL to prevent recurrent pancreatitis 1
3. Patients NOT on Statins (Pre-Statin Era Data)
- Fibrates showed benefit for non-fatal MI in patients not receiving statins (RR 0.69) 3
- However, in patients already on statins, fibrates showed NO significant effect (RR 0.96) 3
- This is critical: in the modern era where statins are standard of care, fibrate benefit essentially disappears 3
Critical Caveat: Fibrates + Statins = No Benefit
When added to statin therapy, fibrates provide no additional cardiovascular benefit 5, 3. The 2014 meta-analysis definitively showed that in the statin era, fibrates do not reduce cardiovascular events 3. Two trials evaluating fibrates with background statin use showed no benefits in preventing cardiovascular events 4.
Clinical Algorithm for Fibrate Use
DO NOT prescribe fibrates for:
- Mortality reduction (any cause)
- Patients with triglycerides <200 mg/dL
- Patients already on adequate statin therapy for cardiovascular risk reduction
- Primary cardiovascular prevention in the statin era
CONSIDER fibrates for:
- Pancreatitis prevention: Triglycerides ≥500-1000 mg/dL (strong indication) 1
- Modest cardiovascular event reduction: Triglycerides ≥200 mg/dL in patients NOT on statins (weak indication, no mortality benefit) 1
Target non-HDL cholesterol per NCEP ATP guidelines as the treatment goal, not triglycerides alone 1
Safety Considerations
Fibrates are generally well-tolerated but cause:
- Increased serum creatinine (common, RR 1.99) 2
- Gastrointestinal discomfort 1
- Possible increased cholesterol gallstones 1
- No significant increase in serious adverse events overall 4, 2
Note on clofibrate: Older meta-analyses showing fibrate benefit often included clofibrate data. When clofibrate (discontinued in 2002 due to safety concerns) is excluded, fibrates lose effectiveness for the primary composite outcome 6.